Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2)

The ERS International Congress 2020, Virtual

This annual event brings together the world's respiratory experts to showcase all the latest advances in respiratory medicine and science.

Due to the COVID-19 pandemic, in 2020 the ERS International Congress took place for the first time in a completely virtual format.

ALERT: Pneumothorax, cough, PAH, alveolar proteinosis

Chair(s): R. Gosens (Groningen, Netherlands), O. Burghuber (Wien, Austria)

Session type: Clinical trials session

Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2)

L. McGarvey (Belfast, United Kingdom), S. Birring (London, United Kingdom), A. Morice (Cottingham, United Kingdom), P. Dicpinigaitis (New York, United States of America), I. Pavord (Oxford, United Kingdom), J. Schelfhout (Kenilworth, United States of America), A. Martin Nguyen (Kenilworth, United States of America), Q. Li (Kenilworth, United States of America), A. Tzontcheva (Kenilworth, United States of America), B. Iskold (Kenilworth, United States of America), S. Green (Kenilworth, United States of America), C. La Rosa (Kenilworth, United States of America), D. Muccino (Kenilworth, United States of America), J. Smith (Manchester, United Kingdom)

CDN Connection Issue

The ERS International Congress 2020, Virtual

Limited Access

#{title}